{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-013677","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.474803+00:00","generated_at":"2026-05-15T02:51:11.870480+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Harvard Apparatus Regenerative Technology treats first patient in Phase 1 esophageal implant trial","bullets":["First patient treated with Cellspan Esophageal Implant (CEI) in Phase 1 clinical trial at Mayo Clinic.","Phase 1 trial is a feasibility and safety study in up to 10 patients under an FDA-approved IND, with three active clinical sites.","Primary endpoint: establishment of a continuous biological neoconduit by three months post-surgery; secondary: mucosal lining by 12 months.","CEI combines a polyurethane scaffold with autologous adipose-derived mesenchymal stromal cells; scaffold removed endoscopically at 21-42 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-013677","json":"https://secwatch.observer/filing/0001437749-26-013677.json","markdown":"https://secwatch.observer/filing/0001437749-26-013677.md","text":"https://secwatch.observer/filing/0001437749-26-013677.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000143774926013677/0001437749-26-013677-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000143774926013677/hrgn20260427_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:51:11.870480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}